



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Tibulizumab

Cat. No.:	HY-P99563
CAS No.:	1849636-24-3
Target:	TNF Receptor; Interleukin Related
Pathway:	Apoptosis; Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with K _d values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research ^[1] .	
IC₅₀ & Target	IL-17A 14 pM (K _d)	BAFF 60 pM (K _d)
In Vitro	<p>Tibulizumab (LY 3090106) binds to mouse BAFF with a K_D of 340 nM and does not bind to mouse IL-17. Tibulizumab binds to cynomolgus BAFF and cynomolgus IL-17 with K_D of 26.8 pM and 19 pM, respectively^[1].</p> <p>In HT-29 cells, Tibulizumab antagonizes the IL-17-induced secretion of CXCL1 in a concentration-dependent manner (IC₅₀ of 2.00 nM). In T1165 cells, Tibulizumab blocks BAFF-induced proliferation in a concentration-dependent manner (IC₅₀ of 0.064 nM). Tibulizumab simultaneously binds and blocks both BAFF and IL-17^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	
In Vivo	<p>Tibulizumab (LY 3090106; 660 µg/mouse, i.p; 66 µg/mouse, s.c) effectively antagonizes the biological effects induced by human BAFF and IL-17 in the mouse^[1].</p> <p>In cynomolgus monkey, Tibulizumab (i.v, 0.3, 1, 5, or 20 mg/kg; or s.c, 5 mg/kg) suppresses B cell development and survival and remains functionally intact in circulation, with a prolonged half-life^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	

REFERENCES

[1]. Robert J Benschop, et al. Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. MABs. 2019 Aug/Sep;11(6):1175-1190.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA